Docetaxel Injection, Solution
Product Images NDC 0409-0201

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Docetaxel (NDC 0409-0201). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hospira, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Docetaxel 01)

Chemical structure diagram of Docetaxel showing its molecular arrangement and bonds. This illustration depicts the spatial configuration of atoms and functional groups within the Docetaxel molecule.*

FDA Label Image

Figure 1 (TAX316 Disease Free Survival K-M Curve)

A Kaplan-Meier curve titled 'TAX316 Disease Free Survival K-M Curve' showing disease-free survival probability (%) over time in months. Two curves are plotted, labeled TAC and FAC, depicting disease-free survival rates across approximately 66 months.*

FDA Label Image

Figure 2 (TAX316 Overall Survival K M Curve)

A Kaplan-Meier survival curve graph titled 'TAX316 Overall Survival K-M Curve' comparing survival probability (%) over survival time (months) between two groups labeled TAC and FAC. The graph shows survival probabilities decreasing over time for both groups with TAC maintaining slightly higher survival probabilities than FAC throughout the observed period up to 66 months.*

FDA Label Image

Figure 3 (TAX317 Survival K-M Curves)

A Kaplan-Meier survival curve graph comparing overall survival for Docetaxel 75 mg/m² versus best supportive care (BSC). The x-axis shows survival time in months, and the y-axis shows cumulative probability of survival. Two lines represent treatment groups, with a log-rank p value of 0.010 indicating statistical significance.*

FDA Label Image

Figure 4 (TAX320 Survival K-M Curves)

A Kaplan-Meier survival curve graph comparing survival times in months for Docetaxel 75 mg/m² versus Vinorelbine or Ifosfamide control. The y-axis shows cumulative probability, and the x-axis shows survival time in months up to 21 months. Two survival curves are shown with a log-rank p-value of 0.13 indicating overall survival comparison.*

FDA Label Image

Figure 5 (TAX327 Survival K-M Curves)

A Kaplan-Meier survival curve graph titled "Figure 5 - TAX327 Survival K-M Curves" showing survival probability over time in months. The graph compares two treatment groups, labeled T75 q3w and M q3w, with survival probability plotted on the vertical axis and survival time in months on the horizontal axis, spanning 0 to 30 months.*

FDA Label Image

Figure 6 -gastric Cancer Study (tax325) Time To Progression K-m Curve (Docetaxel 07)

A Kaplan-Meier curve from a gastric cancer study (TAX325) showing time to progression over 24 months. The graph plots probability (%) on the y-axis against time in months on the x-axis. Two treatment groups are compared: TCF (solid line) and CF (dashed line), illustrating differences in progression timing.*

FDA Label Image

Figure 7 -gastric Cancer Study (tax325) Survival K-m Curve (Docetaxel 08)

A Kaplan-Meier survival curve chart titled 'Gastric Cancer Study (TAX325) Survival K-M Curve' comparing survival probability over time (in months) for two groups labeled TCF and CF. The y-axis shows survival probability as a percentage from 0 to 100%, and the x-axis shows survival time in months from 0 to 36.*

FDA Label Image

Figure 8 -tax323 Progression-free Survival K-m Curve (Docetaxel 09)

A Kaplan-Meier curve depicting progression-free survival probability (%) over time in months for two groups labeled TPF and PF. The graph shows a decline in survival probability for both groups from 0 to 42 months, with the TPF group maintaining higher probabilities throughout most of the timeline.*

FDA Label Image

Figure 9 -tax323 Overall Survival K-m Curve (Docetaxel 10)

Kaplan-Meier curve titled 'Figure 9 -TAX323 Overall Survival K-M Curve' depicting survival probability over time in months. Two survival curves are shown: one solid line for TPF and one dash-dotted line for PF, with survival probability decreasing from near 100% to below 20% over approximately 72 months.*

FDA Label Image

Figure 10 (TAX324 Overall Survival K-M Curve)

A Kaplan-Meier survival curve titled 'Figure 10 - TAX324 Overall Survival K-M Curve' comparing survival probabilities over 72 months between two groups: TPF (n=255) and PF (n=246). The graph includes survival probabilities on the y-axis and survival time in months on the x-axis, with a table showing number of patients at risk over time for both groups.*

FDA Label Image

Docetaxel 11a

FDA Label Image

Docetaxel 11b

FDA Label Image

Principal Display Panel (2 mL Vial Label)

Label for Docetaxel Injection, USP 10 mg/mL, 20 mg/2 mL single-dose vial. The label includes dosage strength, instructions for intravenous use, and cautions about preparation and storage between 20°C to 25°C. It is distributed by Hospira, Inc., Lake Forest, IL.*

FDA Label Image

Principal Display Panel (2 mL Vial Carton)

Packaging label for Docetaxel Injection, USP 20 mg/2 mL (10 mg/mL) by Hospira, Inc. The label indicates this is a single-dose vial ready to add to infusion solution, with warnings to check concentration prior to preparation and to keep out of reach of children. The label includes storage instructions and highlights that the product is for intravenous use only and is a cytotoxic agent.*

FDA Label Image

Principal Display Panel (8 mL Vial Label)

Label for Docetaxel Injection, USP 80 mg/8 mL (10 mg/mL) in an 8 mL multiple-dose vial. The label indicates sterile, intravenous use only, with warnings to protect from light and that the product is cytotoxic. It is distributed by Hospira, Inc., Lake Forest, IL. Contains concentration and storage information.*

FDA Label Image

Principal Display Panel (8 mL Vial Carton)

Packaging label for Docetaxel Injection, USP, 80 mg/8 mL (10 mg/mL) by Hospira, Inc. The label indicates a single 8 mL multiple-dose vial, ready to add to infusion solution. It includes warnings, storage instructions, and cautions for intravenous use with cytotoxic agent notice.*

FDA Label Image

Principal Display Panel (16 mL Vial Label)

Label for Docetaxel Injection, USP 10 mg/mL in a 16 mL multiple-dose vial by Hospira, Inc. The label states active ingredient concentration, dosage form for intravenous use, and cautions including cytotoxic agent warning. It includes storage instructions, package NDC 0409-0201-20, and a barcode.*

FDA Label Image

Principal Display Panel (16 mL Vial Carton)

Docetaxel Injection, USP 160 mg/16 mL (10 mg/mL) carton label from Hospira, Inc. The label states the product is a ready-to-add infusion solution for intravenous use only, supplied in a single multiple-dose vial. It includes red warning bands to check concentration prior to preparation and storage instructions between 20°C to 25°C, with stability of up to 28 days when refrigerated. The label also highlights it is a cytotoxic agent and has instructions to see the package insert for dosage and handling.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.